Compare SACH & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SACH | CING |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | United States |
| Employees | 27 | 14 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.5M | 59.3M |
| IPO Year | N/A | N/A |
| Metric | SACH | CING |
|---|---|---|
| Price | $0.96 | $5.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $2.00 | ★ $34.50 |
| AVG Volume (30 Days) | 251.6K | ★ 372.7K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 19.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $145.00 | N/A |
| Revenue Next Year | $6.80 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $3.16 |
| 52 Week High | $1.45 | $11.89 |
| Indicator | SACH | CING |
|---|---|---|
| Relative Strength Index (RSI) | 40.91 | 55.86 |
| Support Level | $0.91 | $4.94 |
| Resistance Level | $1.12 | $6.67 |
| Average True Range (ATR) | 0.03 | 0.40 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 28.42 | 53.33 |
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns the majority of its revenue through Interest income from loans.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.